Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (5610)	9/18/1998 3:11:00 PM
From: flickerful	Respond to of 9523

points very well taken....i agree on all counts.<eom>

To: Anthony Wong who wrote (5610)	9/18/1998 3:51:00 PM
From: Anthony Wong	Respond to of 9523

Pfizer, Two Others Settle U.S. Charges Over Head Lice Treatment Bloomberg News September 18, 1998, 2:16 p.m. ET Pfizer, Two Others Settle U.S. Charges Over Head Lice Treatment Washington, Sept. 18 (Bloomberg) -- Pfizer Inc. and two other makers of head-lice treatments agreed to change advertisements that federal regulators said included false and unsubstantiated claims. Along with Pfizer, Care Technologies Inc. and a subsidiary of Del Laboratories Inc. marketed lice treatments with the same active ingredients that the U.S. Federal Trade Commission alleges are less than completely effective. The ads claimed the products were effective. ''With 6 to 10 million kids a year dealing with head lice infestations, parents and care givers must be able to trust the ads they see for over-the-counter treatments,'' said Jodie Bernstein, director of the FTC's Bureau of Competition. Pfizer, one of the nation's largest makers of pharmaceuticals and consumer products, said its RID anti-louse product cured infestation in a single treatment and the comb used to remove lice eggs is 100 percent effective. The FTC said the claims are false and Pfizer improperly cited a clinical study on the product that used professionals to test the product rather than average consumers. Pfizer spokesman Bob Fauteux said company ads already reflect its agreement with the FTC. ''This wasn't a matter of RID's efficacy,'' said Fauteux. ''It continues to be safe and effective.'' Officials of Del Labs and Care Technologies, accused of similar misleading claims, weren't immediately available for comment. Del Pharmaceuticals makes Pronto head-lice treatment, and Care Technologies makes Clear Lice Egg Remover and Clear Lice Killing Shampoo. The FTC also said ads for Del's Baby Orajel Tooth & Gum Cleanser falsely claim nine of 10 pediatricians recommend the product. In agreements with the FTC, all three companies are banned from making claims that aren't supported by reliable scientific data. The agreements also prohibit the companies from misrepresenting test results or research for head-lice treatments. The FTC voted unanimously to approve the settlements, which become final after a 60-day public review. --Anne Marie Squeo in Washington at 202-624-1862 /jhr